Insider Selling: Masimo Co. (MASI) Director Sells 10,000 Shares of Stock

Masimo Co. (NASDAQ:MASI) Director Steven Barker sold 10,000 shares of Masimo stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the director now owns 74,832 shares of the company’s stock, valued at $10,102,320. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Steven Barker also recently made the following trade(s):

  • On Monday, April 1st, Steven Barker sold 10,000 shares of Masimo stock. The shares were sold at an average price of $140.00, for a total transaction of $1,400,000.00.
  • On Monday, February 25th, Steven Barker sold 5,877 shares of Masimo stock. The shares were sold at an average price of $130.00, for a total transaction of $764,010.00.

Shares of NASDAQ MASI traded up $0.18 during midday trading on Friday, reaching $122.47. 791,180 shares of the company were exchanged, compared to its average volume of 495,935. The stock has a market cap of $6.53 billion, a PE ratio of 40.42, a PEG ratio of 2.55 and a beta of 1.19. Masimo Co. has a one year low of $88.09 and a one year high of $141.05.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, February 26th. The medical equipment provider reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.11. The firm had revenue of $223.10 million for the quarter, compared to analysts’ expectations of $220.96 million. Masimo had a net margin of 22.55% and a return on equity of 19.53%. The company’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.72 earnings per share. As a group, analysts expect that Masimo Co. will post 3.08 EPS for the current year.

A number of research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Masimo from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. Needham & Company LLC reissued a “buy” rating and issued a $139.00 price objective on shares of Masimo in a research note on Friday, February 1st. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $140.00 price objective on shares of Masimo in a research note on Wednesday, February 27th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Masimo currently has an average rating of “Buy” and an average target price of $137.75.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. West Oak Capital LLC acquired a new position in shares of Masimo during the first quarter worth $28,000. Claybrook Capital LLC acquired a new position in shares of Masimo during the fourth quarter worth $25,000. Ruggie Capital Group acquired a new position in shares of Masimo during the fourth quarter worth $33,000. Financial Gravity Companies Inc. acquired a new position in shares of Masimo during the fourth quarter worth $49,000. Finally, Quantamental Technologies LLC acquired a new position in shares of Masimo during the fourth quarter worth $43,000. 83.88% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/masimo-co-masi-director-steven-barker-sells-10000-shares.html.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.